PainReform Stock (NASDAQ:PRFX)


OwnershipChart

Previous Close

$1.40

52W Range

$0.43 - $16.63

50D Avg

$1.93

200D Avg

$2.18

Market Cap

$2.82M

Avg Vol (3M)

$1.42M

Beta

0.62

Div Yield

-

PRFX Company Profile


PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

2

IPO Date

Sep 01, 2020

Website

PRFX Performance


Peer Comparison


TickerCompany
IMCCIM Cannabis Corp.
MTVAMetaVia Inc.
LIXTLixte Biotechnology Holdings, Inc.
VRPXVirpax Pharmaceuticals, Inc.
NLSPNLS Pharmaceutics AG
MDIAMediaCo Holding Inc.